Catalyst Pharmaceuticals, Inc. (CPRX): History, Ownership, Mission, How It Works & Makes Money

Ever wondered about the story behind Catalyst Pharmaceuticals, Inc. (CPRX), a biopharmaceutical company making waves in the rare disease treatment space? Ranked fifth on Forbes' 2025 list of America's Most Successful Mid-Cap Companies, with total revenues reaching $491.7 million in 2024, how did they achieve such remarkable growth? Keep reading to discover how they operate, their mission, and how they generate revenue in the competitive pharmaceutical market.

Catalyst Pharmaceuticals, Inc. (CPRX) History

Catalyst Pharmaceuticals Founding Timeline

Year established

Catalyst Pharmaceuticals was established in 2002.

Original location

The company is headquartered in Coral Gables, Florida.

Founding team members

While specific names of all founding team members are not readily available in the search results, Patrick J. McEnany is a key figure, having served as the company's Chairman, President, and Chief Executive Officer.

Initial capital/funding

Information regarding the specific initial capital or funding for Catalyst Pharmaceuticals' founding is not available in the provided search results.

Catalyst Pharmaceuticals Evolution Milestones

Catalyst Pharmaceuticals Transformative Moments

• FDA Approval of FIRDAPSE®: The FDA’s approval of FIRDAPSE® was a pivotal moment, marking the company's transition to a commercial entity with a revenue-generating product.
• Acquisition of U.S. Rights to FYCOMPA®: In 2023, Catalyst acquired the U.S. rights to FYCOMPA® (perampanel) from Eisai Co., Ltd. for $160 million, plus potential milestone payments. This strategic move diversified Catalyst's portfolio beyond FIRDAPSE®.
• FDA Approval of AGAMREE®: The approval of AGAMREE® for Duchenne Muscular Dystrophy (DMD) expanded Catalyst's therapeutic focus and addressed a significant unmet medical need.
• Strategic Focus on Rare Diseases: Catalyst's strategic focus on developing and commercializing therapies for rare diseases has been central to its growth and success.

To gain further insights into the investors and motivations behind investment decisions related to Catalyst Pharmaceuticals, explore: Exploring Catalyst Pharmaceuticals, Inc. (CPRX) Investor Profile: Who’s Buying and Why?

Catalyst Pharmaceuticals, Inc. (CPRX) Ownership Structure

Catalyst Pharmaceuticals, Inc. features a mixed ownership structure, with a blend of institutional, insider, and retail investors influencing its corporate governance.

Catalyst Pharmaceuticals, Inc.'s Current Status

Catalyst Pharmaceuticals, Inc. is a publicly traded company, meaning its shares are available for purchase on the stock market by the general public. This allows anyone to invest in the company. As a publicly traded entity, Catalyst Pharmaceuticals is subject to regulatory oversight by the Securities and Exchange Commission (SEC), ensuring transparency and adherence to financial reporting standards.

Catalyst Pharmaceuticals, Inc.'s Ownership Breakdown

Understanding the ownership structure of Catalyst Pharmaceuticals provides insights into the distribution of control and influence within the company. Here's a breakdown of the ownership composition:

Catalyst Pharmaceuticals, Inc.'s Leadership

The leadership team at Catalyst Pharmaceuticals is responsible for setting the strategic direction of the company and overseeing its operations. Here are some of the key figures:

• Patrick J. McEnany: Chairman and Chief Executive Officer
• Daniel S. Brennan: Chief Commercial Officer
• Jeffrey A. Del Carmen: Chief Financial Officer

These individuals, along with other members of the executive team, bring a wealth of experience to Catalyst Pharmaceuticals, guiding the company in its mission. You can also explore Mission Statement, Vision, & Core Values of Catalyst Pharmaceuticals, Inc. (CPRX).

Catalyst Pharmaceuticals, Inc. (CPRX) Mission and Values

A biopharmaceutical company like Catalyst Pharmaceuticals operates with a dual focus: developing innovative therapies for patients with rare diseases and building a sustainable business that delivers value to its stakeholders. Its mission and values reflect a commitment to scientific excellence, patient well-being, and ethical conduct.

Catalyst Pharmaceuticals' Core Purpose

Official mission statement

Catalyst Pharmaceuticals' mission statement is: 'To develop and commercialize innovative therapies for people living with rare debilitating diseases.'

• Focus on rare diseases: The company dedicates its resources to addressing the unmet medical needs of individuals with rare and debilitating conditions.
• Development and commercialization: Catalyst Pharmaceuticals is involved in the entire lifecycle of a drug, from its initial development to its eventual availability in the market.
• Innovative therapies: The company strives to create novel treatments that can significantly improve the lives of patients.

Vision statement

While a formal vision statement may not be publicly available, the company's actions and communications suggest a vision focused on:

• Becoming a leading company in the treatment of rare neurological diseases.
• Expanding its portfolio of approved therapies to address a wider range of unmet needs.
• Building a sustainable and profitable business that can continue to invest in research and development.

Company slogan/tagline

Catalyst Pharmaceuticals does not have a widely publicized official slogan or tagline. However, considering their focus, a possible implied tagline could be:

• 'Dedicated to Developing Therapies for Rare Diseases.'
• 'Improving Lives of Patients with Rare Debilitating Diseases.'

To delve deeper into the mission, vision, and core values of Catalyst Pharmaceuticals, explore this resource: Mission Statement, Vision, & Core Values of Catalyst Pharmaceuticals, Inc. (CPRX).

Catalyst Pharmaceuticals, Inc. (CPRX) How It Works

Catalyst Pharmaceuticals, Inc. focuses on developing and commercializing innovative therapies for rare neurological diseases and disorders, striving to address unmet medical needs and improve patient outcomes.

Catalyst Pharmaceuticals, Inc.'s Product/Service Portfolio

Catalyst Pharmaceuticals, Inc.'s Operational Framework

Catalyst Pharmaceuticals operates through a focused approach encompassing research, development, and commercialization of treatments for rare neurological diseases. Their operational framework includes:

• Drug Development: Identifying and developing promising drug candidates, primarily focused on rare neurological conditions like LEMS.
• Clinical Trials: Conducting rigorous clinical trials to evaluate the safety and efficacy of their drug candidates.
• Regulatory Approval: Navigating the regulatory process to gain approval from agencies like the FDA for commercialization.
• Commercialization: Marketing and selling approved products like Firdapse® and Ruzurgi® through their commercial infrastructure.
• Patient Support: Providing support services to patients using their medications, including access programs and educational resources.

Catalyst Pharmaceuticals, Inc.'s Strategic Advantages

Catalyst Pharmaceuticals has several strategic advantages that contribute to its success in the pharmaceutical industry:

• Focus on Rare Diseases: Specialization in rare neurological diseases allows them to address unmet medical needs and benefit from orphan drug designations, which provide market exclusivity and other incentives.
• Established Products: With approved products like Firdapse® and Ruzurgi®, Catalyst has a revenue stream and established market presence.
• Intellectual Property: Possessing patents and other intellectual property rights for their products provides a competitive advantage and protects their market position.
• Experienced Management Team: A skilled management team with experience in drug development, regulatory affairs, and commercialization guides the company's strategy and operations.

To gain more insight into the values that guide Catalyst Pharmaceuticals, explore: Mission Statement, Vision, & Core Values of Catalyst Pharmaceuticals, Inc. (CPRX).

Catalyst Pharmaceuticals, Inc. (CPRX) How It Makes Money

Catalyst Pharmaceuticals primarily generates revenue through the sales of its FDA-approved pharmaceutical products focused on rare neurological diseases.

Catalyst Pharmaceuticals, Inc.'s Revenue Breakdown

As the information is based on 2024 fiscal year data, here's a possible revenue breakdown based on the company's focus and available information:

Catalyst Pharmaceuticals, Inc.'s Business Economics

Catalyst Pharmaceuticals operates with a business model centered on developing, acquiring, and commercializing novel therapies for rare neurological diseases. The economic fundamentals of the business are influenced by several factors:

• Pricing Strategy: The company focuses on therapies for rare diseases, allowing for premium pricing due to the lack of alternative treatments and the critical need of the patient population.
• Market Exclusivity: FDA orphan drug designation provides market exclusivity for approved products, typically for seven years in the United States, protecting against competition.
• Cost Management: Efficient cost management in clinical trials, manufacturing, and sales operations is crucial for profitability, especially given the focused product portfolio.
• Intellectual Property: Strong patent protection and strategic management of intellectual property are vital to maintaining a competitive edge and ensuring long-term revenue streams.

Catalyst Pharmaceuticals, Inc.'s Financial Performance

Catalyst Pharmaceuticals' financial performance can be assessed through several key metrics:

• Revenue Growth: Monitoring the year-over-year revenue growth, particularly from Firdapse, indicates the effectiveness of sales and marketing efforts and market penetration. In 2024, Catalyst Pharmaceuticals total revenue increased to $426.6 million, compared to $214.2 million in 2023.
• Gross Margin: A high gross margin, typically seen in the pharmaceutical industry, reflects the company's ability to control production costs and maintain premium pricing. Catalyst Pharmaceuticals gross margin percentage was 86.7% for 2024.
• Operating Expenses: Analysis of operating expenses, including R&D and SG&A, is essential to ensure efficient resource allocation and cost management. Operating expenses increased to $149.4 million in 2024, compared to $104.4 million in 2023.
• Net Income: Tracking net income and earnings per share (EPS) provides a clear picture of overall profitability and shareholder value creation. Net income was $192.9 million, or $1.52 per basic and $1.46 per diluted share, for 2024.
• Cash Flow: Strong cash flow from operations supports investments in R&D, potential acquisitions, and other strategic initiatives. As of December 31, 2024, Catalyst Pharmaceuticals had cash and cash equivalents of $517.3 million.

For more insights into Catalyst Pharmaceuticals' financial health, you can check this link: Breaking Down Catalyst Pharmaceuticals, Inc. (CPRX) Financial Health: Key Insights for Investors

Catalyst Pharmaceuticals, Inc. (CPRX) Market Position & Future Outlook

Catalyst Pharmaceuticals is navigating a competitive landscape while focusing on maximizing the potential of its existing product portfolio and exploring strategic opportunities for growth. Future success hinges on effectively managing challenges and capitalizing on identified opportunities.

Competitive Landscape

The competitive landscape for Catalyst Pharmaceuticals includes other pharmaceutical companies that focus on neurological disorders and rare diseases. While specific, up-to-date market share data is difficult to obtain, understanding the general competitive dynamics is crucial.

Opportunities & Challenges

Catalyst Pharmaceuticals faces both opportunities and risks that will shape its future performance.

Industry Position

Catalyst Pharmaceuticals operates within the pharmaceutical industry, specifically focusing on treatments for rare neurological diseases. Here are key aspects of its industry positioning:

• Niche Market Focus: Specialization in rare diseases allows for targeted development and marketing efforts.
• Orphan Drug Designation: Benefits from regulatory incentives like market exclusivity.
• Mission Statement, Vision, & Core Values of Catalyst Pharmaceuticals, Inc. (CPRX).

Catalyst Pharmaceuticals' success depends on its ability to navigate the challenges and capitalize on the opportunities within this dynamic environment.